In patients with common variable immunodeficiency (CVI), we have previously defined a subgroup of patients (CVIHypm,) characterized by decreased numbers of CD4+ lymphocytes in peripheral blood, splenomegaly, and persistent immune activation in vivo, particularly of monocytes/macrophages. To further characterize this hyperactivity, parameters of activation of the tumor necrosis factor (TNF) system (TNFcu and soluble TNF receptors [sTNFRs]) were measured in 24 patients with CV1 and 20 healthy controls. Patients with CV1 had significantly higher serum levels of TNFa and both types of sTNFRs, with the highest levels in the CVI , , . . subgroup. In vitro, peripheral blood mononuclear cells (PBMC) and puri-UMOR NECROSIS FACTOR-a (TNFa), a polypeptide cytokine produced mainly by activated mononuclear phagocytes, has been shown to have pleiotropic biologic functions, including cytotoxic and antitumor activities, and important roles in inflammatory, immunoregulatory, and proliferative responses. ' While TNFa may serve as an essential element in host defense, excessive tissue production can mediate detrimental systemic effects. Thus, increased TNFa production has been implicated in the pathogenesis of both acute (eg, septic shock2 and cerebral malaria3) and chronic diseases (eg, AIDS4 and rheumatoid arthritis5). TNFa mediates its activities after binding to two distinct high-affinity TNF receptors (TNFRs), identified as the 55-kD (p55) and 7 . 5 4 3 (p75) TNFRs.'.' Soluble portions of the extracellular domains of the two surface TNFRs, referred to as soluble p55-TNFR and soluble p75-TNFR:'" are naturally occurring TNFa inhibitors that may block cytotoxicity and inflammatory changes induced by TNFa in vivo and in vitro.' ' , l 2 Considerable controversy exists concerning the biologic function of naturally occurring soluble cytokine receptors. I 3 Nevertheless, accumulating evidence indicates that the biologic effects of TNFa may partly depend on the balance between TNFa and soluble TNFRs (sTNFRs) and that 
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Common variable immunodeficiency (CVI) comprises a heterogeneous group of B-cell deficiency syndromes.14." It seems that the B cells in many of these patients are not necessarily intrinsically defective and that inappropriate Tcell help may be of importance in the induction of immunodeficiency." In addition, signs of monocyteJmacrophage hyperactivity have been demonstrated in subgroups of patients with CVI,"." and we have defined a subgroup of patients characterized by persistent immune activation in vivo, decreased numbers of CD4+ lymphocytes in peripheral blood, and splen~megaly.'"'~ Recently, we also found increased serum levels of TNFa in CVI.*"
On the basis of these observations, we have hypothesized that persistent activation of the TNF system may be of importance in the immunopathogenesis of certain CV1 subgroups. In the present study, we used various experimental approaches to explore this hypothesis. We analyzed levels of TNFa and sTNFRs and the balance between these parameters in patients with CV1 and healthy controls, both in vivo and in vitro. We also tested if these TNF parameters were related to important clinical and immunologic characteristics of patients with CVI.
MATERIALS AND METHODS
Study population. Twenty-four patients with CV1 were consecutively enrolled in the present study (Table I ). The diagnosis of CV1 was defined as previously de~cribed.'~,'' Based on previously defined criteria,'" 13 patients had splenomegaly, nine had chronic rhinosinusitis, five had nodular intestinal lymphoid hyperplasia (NILH), four had bronchiectasis, two had chronic hepatitis C virus (HCV) infection, three had autoimmune disorders, and two patients had noncaseating granulomata. At the time of the study, all patients had been treated with subcutaneous self-administered immunoglobulin for a minimum of 24 months. No patients showed any signs of overt infection at the time of blood collection ( 3 weeks before to 1 week after). None were taking antibiotics or immunosuppressive drugs. Controls in the study were 20 sex-and age-matched healthy blood donors (Table I ) .
Blood sumpling protocol. Blood samples in study were drawn just before immunoglobulin administration.
For serum sampling, sterile vacuum blood collection tubes without any additives were immediately immersed in melting ice and were allowed to clot for less than 1 hour before centrifugation at 400g for 10 minutes. Serum was collected and stored at -70°C in multiple aliquots until analysis. Serum samples for cytokine analysis were frozen and thawed only once. Cells. Peripheral blood mononuclear cells (PBMC) were obtained from heparinized blood by Isopaque-Ficoll gradient centrifugation within 2 hours after blood sampling, as described elsewhere."
Mononuclear cells were resuspended in RPM1 1640 (Gibco, Paisley, UK) with 2 mmoVL L-glutamine supplemented with gentamicin (40 pg/mL) and 10% heat-inactivated pooled human AB+ serum (culture medium). The fractions of monocytes (CD14+) and T lymphocytes (CD2+) were determined by immunomagnetic quantification. 22 Isolation of monocytes was performed by plastic adherence as previously described." The endotoxin level of the culture medium was less than 10 pg/mL (limulus amebocyte lysate test).
Cell stimulation. For evaluation of TNFa and sTNFR concentrations in cell supernatants, PBMC (3 X 106/mL) or monocytes (3 X 105/mL) were incubated in flat-bottomed, 96-well trays (Costar, Cambridge, MA; PBMC) or 24-well trays (Costar; monocytes) with or without stimulants (lipopolysaccharide from Escherichia coli 026:B6 [LPS; final concentration, 10 ng/mL; Sigma Chemical, St Louis, MO] and staphylococcal enterotoxin B [SEB; final concentration, 10 ng/mL; Sigma]). After various time periods, cell-free supernatants were harvested and stored at -70°C in several aliquots until analysis.
Enzyme immunoassays (EIAs) for detection of sTNFRs and TNFa. The sTNFRs, p55 and p75, were analyzed by immunoassays described by Liabakk et al.23 Immunoplates were coated with the monoclonal antibodies IV4E and 3H5, recognizing non-TNF-binding sites of p55 and p75 T N F R , respectively. Recombinant human p55 and p75 TNFRs (provided by Dr H. Loetscher, F. Hoffmann-La Roche, Basel, Switzerland) served as standards. TNFa concentration was quantified by EL4 (Medgenix, Fleurus, Belgium) according to the manufacturer's guidelines, as previously d e s~r i b e d .~"~~~ TNF bioassay. TNFa bioactivity was assayed colorimetrically by its cytotoxic effect on the mouse fibrosarcoma cell line WEHI 164 clone 13, essentially as previously described.25
RNA isolation and Northern hybridim'on analyses. Total cellular RNA was isolated from unstimulated and LPS-stimulated monocytes after various time periods by the guanidine isothiocyanate method,% and Northern blot analyses were performed as previously described?' The p55 and p75 TNFR probes were 1.3-kb EcoRI and 2.3-kb EcoRI fragments of human p55' and p 7 9 TNFR cDNA, respectively, and were cloned into pcDNA (In Vitrogen, San Diego, CA), as previously de~cribed.2~ The probes for TNFa @DNA clone pAW742) and the glyceraldehyde-phosphate dehydrogenase (GADPH) gene @DNA clone pHcGAP) were obtained from American Qpe Culture Collection (Rockville, MD). The probes were labeled by random priming with a megaprime DNA labeling kit (Amersham
Int, Little Chalfont, UK)
Blots were washed and autoradiographed using Hyperfilm (Amersham) and Super Rapid Screens (Eastman Kcdak, Rochester, W), and the relative sensitivity of the autoradiographs was quantified using scanning densitometry (Pharmacia LKB, Uppsala, Sweden). When comparing mRNA levels in patients and controls, a quantitative estimate of the TNFa and TNFRs mRNA levels was attempted by comparing with the mRNA level of the GADPH gene.
Measurement of other immunologic parameters. Neopterin levels were determined by a commercially available radioimmunoassay method (IMMUtest Neopterin, Henning Berlin GMBH, Berlin, Germany) as recommended by the manufacturer. The numbers of CD2+, CD4+, CD8+, CD19+ lymphocytes and monocytes were determined by immunomagnetic quantification, which has been shown to agree well with flow cytometry.28
Statistical analysis. For comparison of two groups of individuals, the Mann-Whitney U test was used. When more than two groups were compared, the Kruskal-Wallis test was used. If a significant difference was found, Fisher's least significant differences were computed on the ranks to determine differences between each pair of groups. Coefficients of correlation (r) were calculated by the Spearman rank test. Data are given as medians and 25th to 75th percentiles if not otherwise stated. P values are two-sided and considered significant when less than .05.
RESULTS

Serum levels of TNFa and sTNFRs in patients with CV1 and in controls. As illustrated in Fig 1, patients with CV1
had significantly elevated serum levels of TNFa and sTNFRs compared with healthy controls. Although levels of both types of sTNFRs were raised, the ratio between levels of soluble p75 and p55 receptors was also significantly elevated in patients with CV1 (3.11 [2. 49 to 3.361 v 1.47 [1.12 to 1.761, P < .001; patients with CV1 and controls, respectively]. TNFa bioactivity was not detected in any serum samples from either patients or controls.
Serum levels of TNFa and sTNFRs in patients with CV1 in relation to clinical and immunologic manifestations. We have previously defined a subgroup of patients with CV1 (CVIHyper) characterized by persistent immune activation in vivo, low numbers of CD4+ lymphocytes in peripheral blood, and ~plenomegaly.'~-'~ In the present study, patients were classified as CVIHYPer if they had CD4+ lymphocyte counts less than 4OO X I06/L, serum neopterin levels greater than the mean + 4 SD of controls (23 n m o n ) , and splenomegaly. These characteristics were constant when patients were tested and evaluated at least three times over a minimum of 2 years. As shown in Fig 2, the 11 CVIHWr patients had significantly raised serum levels of TNFa and both types of sTNFRs compared with other patients with CVI.
The ratio between TNFa and sTNFRs may provide an estimate of the molar balance in serum between TNFa molecules and sTNFRs. In molecular terms, this ratio was defined as TNFa (pmol/L)/(p55 + p75)(pmol/L) X 100, assuming a molecular mass of (17 X 3) kD and 30 kD for TNFa (trimer) and both types of sTNFRs, respectively. We found that CVIHyper patients had significantly higher ratios of TNFa to sTNFRs, reflecting an approximate 400-fold molar excess of sTNFRs in the CVIHyper group compared with an approximate 1,000-fold molar excess among the other patients with CV1 (Fig 2) .
Bacterial products such as endotoxins are known to be percentiles. * P < .M1 versus controls; **P < .MO1 versus controls. potent inducers of TNFa.' However, patients with CV1 and chronic rhinosinusitis or bronchiectasis had not significantly higher serum levels of TNFa and sTNFRs than other patients with CV1 (data not shown). Moreover, we found no significant association between occurrence of autoimmunity, chronic HCV infection, or NILH and raised serum levels of TNFa and TNFRs. However, the two patients with noncaseating graulomata were among the five patients with CV1 with highest levels of these TNF parameters (data not shown).
In six CVIHyper patients, six other patients with CVI, and six controls, analyses of TNFa and sTNFRs were performed in serum samples taken at a median period of 9 months (range, 4 to 18 months) before the study, confirming persistently raised levels of TNFa and sTNFRs in patients with CVI. In addition, levels of these TNF parameters were again significantly higher among patients in the CVI,,,, group compared with other patients with CV1 (data not shown). Furthermore, in these six CVIHyFr patients, serum levels of TNFa were measured four times during a period of 2 years, and they always had concentrations above the mean + 5 SD of healthy controls (data not shown).
I n vitro release of TNFa and sTNFRs from PBMC. To further study the activation of the TNF system in patients with CVI, PBMC from six CVI,,ypr patients, seven other patients with CVI, and six healthy controls were stimulated with LPS, and supernatants from stimulated and unstimulated PBMC were harvested after 5, 20, and 72 hours and assayed for quantification of TNFa and sTNFR levels. Among PBMC, monocytes are both the target for LPS and appear in vitro to be the major source of TNFa and soluble p75-TNFR release.','" In the present study, we, therefore, expressed TNFa and sTNFR levels in supernatants as concentration per lo5 monocytes. As illustrated in Fig 3. CVIHype, patients had significantly higher levels of spontaneous TNFa release compared with levels in both other CV1 patients and in healthy controls. Spontaneous in vitro release after only 5 hours might reflect the in vivo situation, and indeed, among patients with CVI, TNFa levels in supernatants at this time point were significantly correlated with TNFa levels in serum ( r = .70, P < .01). In contrast with spontaneous release, CVIHYWr patients had decreased maximum levels of LPSstimulated TNFa release compared with both other patients with CV1 and healthy controls (Fig 3) . Furthermore, among patients with CVI, there was an inverse correlation between serum levels of TNFa and maximum levels of LPS-stimulated TNFa release ( r = .67, P < .01). The significantly increased spontaneous and significantly decreased LPS-stimulated TNFa release in PBMC from CVIH,,,, patients was confirmed when TNFa bioactivity was analyzed in supernatants from three CVIHyPer patients and three controls (data not shown).
In both patients and controls, we observed a gradual increase in LPS-stimulated as well as spontaneous release of sTNFRs, with maximum concentrations for both types of sTNFRs after 72 hours (data not shown). The maximum sTNFR levels are shown in Table 2 , demonstrating significantly higher unstimulated and significantly lower LPS-stimulated soluble p75-TNFR levels in CVIHyper patients compared with other patients with CV1 and controls. Furthermore, soluble p75-TNFR was the predominant sTNFR in PBMC supernatants in both patients with CV1 and controls (Table 2) , and the ratio between soluble p75 and p55 receptors in PBMC supernatants was considerably higher than in serum in both groups (data not shown).
To investigate if the decrease in stimulated release of TNFa and soluble p75-TNFR from PBMC in the CVIH,,,, group was restricted to stimulation with LPS, PBMC from all patients and controls were also stimulated with SEB. We observed similar findings as for LPS response, with preferential release of soluble p75 compared with soluble pSS-TNFR and significantly decreased release of both TNFa and soluble p75-TNFR (expressed both as concentration per IOh PBMC and per IO5 monocytes) in the CVIHyper group (data not shown). Thus, the impaired in vitro release in the C V I H~~~~ group seems not to be restricted to the LPS stimulatory pathway.
In vitro release of TNFa and sTNFRs from isolated monocytes. In a separate experiment, spontaneous and LPS-stimulated TNFa and sTNFR release was measured in isolated monocytes from five controls and five CVIHyper patients Concerning sTNFRs, both unstimulated and LPS-stimulated monocytes almost entirely released soluble p75-TNFR in concentrations suggesting that monocytes are the most important source of soluble p75-TNFR in PBMC (data not shown). CVIHYPer patients tended to have higher spontaneous and lower stimulated soluble p75-TNFR release than controls (data not shown).
To further elucidate the balance between TNFa and TNFRs, we analyzed mRNA levels for TNFa and both types
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of TNFRs in unstimulated and LPS-stimulated monocytes in four CVIHYPer patients and four controls. Two significant findings were revealed. First, in both CVIHyper patients (Fig   4) and controls (data not shown), there was a decrease in LPS-stimulated mRNA levels for p55-TNFR compared with unstimulated levels after 3 hours, before a slight increase was observed after 12 hours. Second, we could not detect any significant differences between patients and controls concerning mRNA levels for either TNFa or TNFRs (data not shown).
The balance between TNFa and sTNFRs in PBMC supematants. As shown in Fig 5, CVIH, patients had significantly higher TNFa-bsTNFR ratios than both other CVI patients and controls in Supernatants from unstimulated cells, while they had significantly lower ratios after LPS stimulation. In both patients and controls, the maximum levels of this ratio were significantly correlated with maximum levels of TNFa bioactivity when eval- 
DISCUSSION
The present study demonstrates that patients with CV1 had significantly and persistently elevated serum levels of TNFa and both types of sTNFRs compared with healthy controls. In addition, spontaneous in vitro release of TNFa from PBMC and monocytes was significantly higher in patients with CV1 than in controls. These findings strongly indicate a persistent activation of the TNF system in patients with CVI, and this activation was particularly pronounced in a subgroup of patients with CV1 previously described by us'"'' and characterized in vivo by chronic immune activation, low numbers of CD4+ lymphocytes, and splenomegaly.
WeI9 and others"' have previously not been able to detect raised serum levels of TNFa in patients with CV1 by other EIAs. This most probably reflects methodologic differences, and we have recently suggested that the EIA used in the present study may better detect TNFa in complex with sTNFRs than other EIAs.*~ In contrast with the increased spontaneous TNFa production, we observed a significant decrease in stimulated TNFa release among CVIHYPer patients both in PBMC and in purified monocytes. A similar dissociation between circulating TNFa levels and in vitro release from mononuclear cells has previously been reported in septicemia3' and in human immunodeficiency virus type 1 (HIV-l) infection. seems that in vivo TNFa activation is characterized by high serum levels and increased spontaneous release of TNFa from monocytes/macrophages, but that this in vivo activation renders the cells less susceptible to further stimulation in ~i t r o .~' .~~ Furthermore, the results of the present study may suggest that the downregulation of the TNFa release after LPS stimulation of monocytes from patients with CV1 is regulated at the posttranscriptional However, further studies are needed to elucidate the mechanism of this downregulation.
Elevated circulating levels of sTNFRs are found in several pathologic, proinflammatory condition^.^^ In the present study, we demonstrate that patients with CV1 are also characterized by markedly elevated serum levels of both types of sTNFRs. The signals and mechanisms that regulate the levels of sTNFRs have not been clarified. However, it seems that TNFa and stimuli causing TNFa release may be important stimuli for release of sTNFRs in v~v o .~~.~' Thus, in vivo 679 activation of the TNF system may be reflected in elevated serum levels of sTNFRs persisting longer in circulation than TNFa i t~e l f .~~.~~
In accordance with recent report^,^*^' we found that both monocytes and PBMC primarily released soluble p75-TNFR both unstimulated and after activation with LPS and SEB, suggesting that the increased circulating levels of soluble p75-TNFR found in CV1 reflect increased release from PBMC and, in particular, from monocytes. However, the relative concentration of soluble p75 compared with soluble p55-TNFR was higher in cell supernatants in comparison with those concentrations found in peripheral blood in both patients with CV1 and controls, suggesting that other cellular sources such as endothelial cells4'" may be important contributers to the circulating levels of soluble p55-TNFRs. Although only a modest increase in soluble p55-TNFR levels are found after LPS stimulation of monocytes, downregulation of membrane p55-TNFR is reported after stimulation of these cell^.'^ This may reflect internalization of the receptor rather than shedding!' In the present study, and not previously reported for mononuclear phagocytes, we also observed a decrease in steady-state mRNA levels for this receptor after LPS stimulation of monocytes from both patients with CV1 and controls, possibly resulting in decreased synthesis.
The molar balance between TNFa and sTNFRs seems to be an important parameter for the activation of the TNF system.I3 We found that CVIHyper patients had significantly higher TNFa:sTNFRs ratios both in serum and in unstimulated PBMC supernatants and significantly lower ratios in PBMC supernatants after LPS stimulation than other patients with CV1 and controls. Interestingly, in PBMC supernatants, this ratio was significantly correlated with levels of TNFa bioactivity. The significance of these findings is uncertain, and the role of sTNFRs in immunologic reactions is not clear. It seems that the systemic TNFa effect depends on the relative concentrations of TNFa and sTNFRs in circulat i~n .~~ However, it appears that sTNFRs may not only have ne~tralizing~~ but also enhancing" effects on T W a activity. It seems that enhancing effects of sTNFRs on TNFa activity are seen in the presence of high TNFa-to-sTNFRs ratios, and inhibitory effects are observed with marked molar excess of STNFRS!~,~ Interestingly, we found that while the TNFato-sTNFRs ratio in serum was low, suggesting an inhibitory effect of sTNFRs, this ratio was high in PMBC supernatants from both patients with CV1 and controls, suggesting a possible enhancing effect of sTNFRs in the cellular microenvironment.
The enhanced and persistent activation of the TNF system seen in CV1 may have both clinical and immunologic consequences. Indeed, persistent TNFa activation has been implicated in the pathogenesis of a number of disorders seen with increased frequency in CVI," eg, autoimmune disorders: granuloma f~rmation:~ and chronic diarrhea and malabsorption in the absence of any known p a t h~g e n .~ TNFa is known to enhance B-and T-cell proliferation and B-cell differentiation after short-time exposure.' However, prolonged TNFa exposure in vivo and in vitro seems to impair lymphocyte proliferation response,"8349 T cell-50 and
680
AUKRUST ET AL natural killer ~ell-mediated~' cytotoxicity, and T-cell interleukin-2 production:' possibly by modulating intracellular redox status." Interestingly, there are also reports of suppressive effects of TNFa exposure on mitogen-induced IgG and IgM production from PBMC."
In addition to possible immunosuppressive effects on B and T cells, the persistent TNFa activation in vivo in CVI, which was associated with impaired TNFa response when further stimulated in vitro, might contribute to depressed microbicidal defense" if a similar refractory state is induced in monocytic cells in vivo.
The present results suggest that sustained TNFa activity partly reflecting monocyte hyperactivity is an important characteristic of the CVIHYFr subgroup. These phenomena may reflect a fundamental immunologic dysfunction in CVI, but they may also be secondary to chronic infections, for example, although we could not relate the activation of the TNF system in CV1 to ongoing bacterial infections. Interestingly, however, chronic viral infection has been suggested to be implicated in the pathogenesis of CVI.53.54 Regardless of the cause of this persistent activation of the TNF system, biologic effects of TNFa may contribute to the pathogenesis both of clinical and immunologic manifestations in subgroups of CVI. It is, therefore, conceivable that therapeutic modulation of the TNF system might be worth exploring in CVI.
